

Massimo Massaia

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2404585/publications.pdf>

Version: 2024-02-01

189
papers

6,767
citations

53660

45
h-index

69108

77
g-index

190
all docs

190
docs citations

190
times ranked

8274
citing authors

#	ARTICLE	IF	CITATIONS
1	A Comparison of Allografting with Autografting for Newly Diagnosed Myeloma. <i>New England Journal of Medicine</i> , 2007, 356, 1110-1120.	13.9	479
2	Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study. <i>Lancet Haematology</i> , 2020, 7, e737-e745.	2.2	430
3	Modulation of tryptophan catabolism by human leukemic cells results in the conversion of CD25 ^{hi} into CD25 ⁺ T regulatory cells. <i>Blood</i> , 2007, 109, 2871-2877.	0.6	357
4	Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial. <i>Blood</i> , 2004, 104, 3052-3057.	0.6	305
5	CEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib. <i>Blood</i> , 2008, 111, 2765-2775.	0.6	239
6	Zoledronic acid repolarizes tumour-associated macrophages and inhibits mammary carcinogenesis by targeting the mevalonate pathway. <i>Journal of Cellular and Molecular Medicine</i> , 2010, 14, 2803-2815.	1.6	228
7	Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia. <i>Blood</i> , 2015, 126, 1921-1924.	0.6	197
8	Early CPAP prevents evolution of acute lung injury in patients with hematologic malignancy. <i>Intensive Care Medicine</i> , 2010, 36, 1666-1674.	3.9	152
9	Idiotype Vaccination in Human Myeloma: Generation of Tumor-Specific Immune Responses After High-Dose Chemotherapy. <i>Blood</i> , 1999, 94, 673-683.	0.6	127
10	Production of tumor necrosis factor-alpha by B-cell chronic lymphocytic leukemia cells: a possible regulatory role of TNF in the progression of the disease. <i>Blood</i> , 1990, 76, 393-400.	0.6	124
11	Production and characterization of monoclonal antibodies to the glycosyl phosphatidylinositol-anchored lymphocyte differentiation antigen ecto-5'-nucleotidase (CD73). <i>Tissue Antigens</i> , 1990, 35, 9-19.	1.0	120
12	Production of tumor necrosis factor-alpha by B-cell chronic lymphocytic leukemia cells: a possible regulatory role of TNF in the progression of the disease. <i>Blood</i> , 1990, 76, 393-400.	0.6	119
13	Effector T cells and tumor cells as immune targets of zoledronic acid in multiple myeloma. <i>Leukemia</i> , 2005, 19, 664-670.	3.3	119
14	Long-term follow-up of a comparison of nonmyeloablative allografting with autografting for newly diagnosed myeloma. <i>Blood</i> , 2011, 117, 6721-6727.	0.6	113
15	Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients. <i>American Journal of Hematology</i> , 2014, 89, 480-486.	2.0	104
16	DISTRIBUTION OF T-CELL SIGNALLING MOLECULES IN HUMAN MYELOMA. <i>British Journal of Haematology</i> , 1997, 97, 810-814.	1.2	100
17	Acute myeloid leukemia cells constitutively express the immunoregulatory enzyme indoleamine 2,3-dioxygenase. <i>Leukemia</i> , 2007, 21, 353-355.	3.3	99
18	Enhanced ability of dendritic cells to stimulate innate and adaptive immunity on short-term incubation with zoledronic acid. <i>Blood</i> , 2007, 110, 921-927.	0.6	98

#	ARTICLE	IF	CITATIONS
19	Telomere length is an independent predictor of survival, treatment requirement and Richter's syndrome transformation in chronic lymphocytic leukemia. <i>Leukemia</i> , 2009, 23, 1062-1072.	3.3	97
20	Melphalan 200 mg/m ² versus melphalan 100 mg/m ² in newly diagnosed myeloma patients: a prospective, multicenter phase 3 study. <i>Blood</i> , 2010, 115, 1873-1879.	0.6	87
21	Immune Modulation by Zoledronic Acid in Human Myeloma: An Advantageous Cross-Talk between V β 3V γ 2 T Cells, I α 1 β 2 CD8+ T Cells, Regulatory T Cells, and Dendritic Cells. <i>Journal of Immunology</i> , 2011, 187, 1578-1590.	0.4	77
22	Distribution of terminal deoxynucleotidyl transferase and purine degradative and synthetic enzymes in subpopulations of human thymocytes. <i>Journal of Immunology</i> , 1982, 129, 1430-5.	0.4	75
23	Early responder myeloma: kinetic studies identify a patient subgroup characterized by very poor prognosis.. <i>Journal of Clinical Oncology</i> , 1989, 7, 119-125.	0.8	72
24	Dysregulated Fas and Bcl-2 expression leading to enhanced apoptosis in T cells of multiple myeloma patients. <i>Blood</i> , 1995, 85, 3679-3687.	0.6	66
25	Long-term follow-up of idiotype vaccination in human myeloma as a maintenance therapy after high-dose chemotherapy. <i>Leukemia</i> , 2004, 18, 139-145.	3.3	63
26	A VEGF-dependent autocrine loop mediates proliferation and capillarogenesis in bone marrow endothelial cells of patients with multiple myeloma. <i>Thrombosis and Haemostasis</i> , 2004, 92, 1438-1445.	1.8	61
27	IGHV unmutated CLL B cells are more prone to spontaneous apoptosis and subject to environmental prosurvival signals than mutated CLL B cells. <i>Leukemia</i> , 2011, 25, 828-837.	3.3	61
28	New drugs for treatment of multiple myeloma. <i>Lancet Oncology</i> , The, 2004, 5, 430-442.	5.1	59
29	Microvesicles released from multiple myeloma cells are equipped with ectoenzymes belonging to canonical and non-canonical adenosinergic pathways and produce adenosine from ATP and NAD ⁺ . <i>Oncolmmunology</i> , 2018, 7, e1458809.	2.1	59
30	Phase I/II clinical trial of sequential subcutaneous and intravenous delivery of dendritic cell vaccination for refractory multiple myeloma using patientâ€specific tumour idiotype protein or idiotype (VDJ)â€derived class Iâ€restricted peptides. <i>British Journal of Haematology</i> , 2007, 139, 415-424.	1.2	58
31	Anti-CD38 Antibody Therapy: Windows of Opportunity Yielded by the Functional Characteristics of the Target Molecule. <i>Molecular Medicine</i> , 2013, 19, 99-108.	1.9	58
32	Anergic bone marrow V β 3V γ 2 T cells as early and long-lasting markers of PD-1-targetable microenvironment-induced immune suppression in human myeloma. <i>Oncolmmunology</i> , 2015, 4, e1047580.	2.1	58
33	The ATP-binding cassette transporter A1 regulates phosphoantigen release and V β 3V γ 2 T cell activation by dendritic cells. <i>Nature Communications</i> , 2017, 8, 15663.	5.8	57
34	COVIDâ€19 elicits an impaired antibody response against SARSâ€CoVâ€2 in patients with haematological malignancies. <i>British Journal of Haematology</i> , 2021, 195, 371-377.	1.2	56
35	Practical management of ibrutinib in the real life: Focus on atrial fibrillation and bleeding. <i>Hematological Oncology</i> , 2018, 36, 624-632.	0.8	55
36	The human myeloma cell line LP-1: a versatile model in which to study early plasma-cell differentiation and c-myc activation. <i>Blood</i> , 1989, 73, 1020-1027.	0.6	54

#	ARTICLE	IF	CITATIONS
37	Human $\hat{3}^1$ T cell responses in infection and immunotherapy: Common mechanisms, common mediators?. <i>European Journal of Immunology</i> , 2012, 42, 1668-1676.	1.6	53
38	Antitumor vaccination: where we stand. <i>Haematologica</i> , 2000, 85, 1172-206.	1.7	53
39	Dysfunctional $\hat{3}^9\hat{V}^2$ T cells are negative prognosticators and markers of dysregulated mevalonate pathway activity in chronic lymphocytic leukemia cells. <i>Blood</i> , 2012, 120, 3271-3279.	0.6	51
40	Human T cell activation. Synergy between CD73 (ecto-5'-nucleotidase) and signals delivered through CD3 and CD2 molecules. <i>Journal of Immunology</i> , 1990, 145, 1664-74.	0.4	51
41	Zoledronic Acid Restores Doxorubicin Chemosensitivity and Immunogenic Cell Death in Multidrug-Resistant Human Cancer Cells. <i>PLoS ONE</i> , 2013, 8, e60975.	1.1	49
42	Activated idiotype-reactive cells in suppressor/cytotoxic subpopulations of monoclonal gammopathies: correlation with diagnosis and disease status. <i>Blood</i> , 1988, 72, 1064-1068.	0.6	48
43	Severe and long-lasting disruption of T-cell receptor diversity in human myeloma after high-dose chemotherapy and autologous peripheral blood progenitor cell infusion. <i>British Journal of Haematology</i> , 2001, 113, 1051-1059.	1.2	48
44	Management of multiple myeloma and related-disorders: guidelines from the Italian Society of Hematology (SIE), Italian Society of Experimental Hematology (SIES) and Italian Group for Bone Marrow Transplantation (GITMO). <i>Haematologica</i> , 2004, 89, 717-41.	1.7	48
45	CD8+CD11b+ peripheral blood T lymphocytes contain lymphokine-activated killer cell precursors. <i>European Journal of Immunology</i> , 1989, 19, 1037-1044.	1.6	46
46	Exposure to myeloma cell lysates affects the immune competence of dendritic cells and favors the induction of Tr1-like regulatory T cells. <i>European Journal of Immunology</i> , 2005, 35, 1155-1163.	1.6	45
47	Activated idiotype-reactive cells in suppressor/cytotoxic subpopulations of monoclonal gammopathies: correlation with diagnosis and disease status. <i>Blood</i> , 1988, 72, 1064-1068.	0.6	44
48	Enzymes of purine metabolism in human peripheral lymphocyte subpopulations. <i>Clinical and Experimental Immunology</i> , 1982, 50, 148-54.	1.1	44
49	Detection of hyperreactive T cells in multiple myeloma by multivalent cross-linking of the CD3/TCR complex [see comments]. <i>Blood</i> , 1991, 78, 1770-1780.	0.6	43
50	Serum levels of tumour necrosis factor- $\hat{1}\pm$ in patients with B-cell chronic lymphocytic leukaemia. <i>European Journal of Cancer</i> , 1994, 30, 1259-1263.	1.3	43
51	Production of tumor necrosis factor-alpha by B-cell chronic lymphocytic leukemia cells: a possible regulatory role of TNF in the progression of the disease. <i>Blood</i> , 1990, 76, 393-400.	0.6	40
52	HIF- $1\pm$ is over-expressed in leukemic cells from TP53-disrupted patients and is a promising therapeutic target in chronic lymphocytic leukemia. <i>Haematologica</i> , 2020, 105, 1042-1054.	1.7	39
53	5'-nucleotidase, adenosine deaminase and purine nucleoside phosphorylase activities in acute leukaemia. <i>Leukemia Research</i> , 1982, 6, 475-482.	0.4	38
54	Idiotype vaccination in human myeloma: generation of tumor-specific immune responses after high-dose chemotherapy. <i>Blood</i> , 1999, 94, 673-83.	0.6	36

#	ARTICLE	IF	CITATIONS
55	Kinetics of circulating B lymphocytes in human myeloma. <i>Blood</i> , 1983, 61, 812-814.	0.6	35
56	Rapid generation of antiplasma cell activity in the bone marrow of myeloma patients by CD3-activated T cells. <i>Blood</i> , 1993, 82, 1787-1797.	0.6	35
57	Nitrogen-Containing Bisphosphonates and Cancer Immunotherapy. <i>Current Pharmaceutical Design</i> , 2010, 16, 3007-3014.	0.9	35
58	VÎ³VÎ² T cell-based immunotherapy in hematological malignancies: from bench to bedside. <i>Cellular and Molecular Life Sciences</i> , 2011, 68, 2419-2432.	2.4	35
59	Correlation between disease activity and T-cell CD3 chain expression in a B-cell lymphoma. <i>British Journal of Haematology</i> , 1994, 88, 886-888.	1.2	33
60	Simvastatin and downstream inhibitors circumvent constitutive and stromal cell-induced resistance to doxorubicin in IGHV unmutated CLL cells. <i>Oncotarget</i> , 2015, 6, 29833-29846.	0.8	33
61	Increasing intratumor C/EBP-Î² LIP and nitric oxide levels overcome resistance to doxorubicin in triple negative breast cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2018, 37, 286.	3.5	32
62	Multiple myeloma: comparison of two dose-intensive melphalan regimens (100 vs 200â€‰mg/m ²). <i>Leukemia</i> , 2004, 18, 133-138.	3.3	30
63	A randomized, openâ€label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab <i>versus</i> fludarabine, cyclophosphamide and rituximab alone in subjects with relapsed chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2014, 167, 466-477.	1.2	30
64	Defective generation of alloreactive cytotoxic T lymphocytes (CTL) in human monoclonal gammopathies. <i>Clinical and Experimental Immunology</i> , 1988, 73, 214-8.	1.1	30
65	Constitutive production of tumor necrosis factor-alpha in hairy cell leukemia: possible role in the pathogenesis of the cytopenia(s) and effect of treatment with interferon-alpha.. <i>Journal of Clinical Oncology</i> , 1992, 10, 954-959.	0.8	29
66	Kaposi's sarcoma triggered by endogenous HHV-8 reactivation after non-myeloablative allogeneic haematopoietic transplantation. <i>European Journal of Haematology</i> , 2006, 76, 342-347.	1.1	29
67	Human myeloma: Several subsets of circulating lymphocytes express plasma cellâ€associated antigens. <i>European Journal of Haematology</i> , 1988, 40, 299-304.	1.1	28
68	SIE, SIES, GITMO evidence-based guidelines on novel agents (thalidomide, bortezomib, and lenalidomide) in the treatment of multiple myeloma. <i>Annals of Hematology</i> , 2012, 91, 875-888.	0.8	28
69	A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study. <i>Blood Advances</i> , 2022, 6, 327-338.	2.5	28
70	The bone marrow of myeloma patients is steadily inhabited by a normal-sized pool of functional regulatory T cells irrespective of the disease status. <i>Haematologica</i> , 2014, 99, 1605-1610.	1.7	27
71	Polyclonal Immunoglobulin E Levels Are Correlated with Hemoglobin Values and Overall Survival in Patients with Multiple Myeloma. <i>Clinical Cancer Research</i> , 2007, 13, 5348-5354.	3.2	26
72	Selective induction of CD73 expression in human lymphocytes by CD38 ligation: a novel pathway linking signal transducers with ecto-enzyme activities. <i>Journal of Immunology</i> , 1996, 157, 4354-62.	0.4	25

#	ARTICLE	IF	CITATIONS
73	Defective interleukin-2 induction of lymphokine-activated killer (LAK) activity in peripheral blood T lymphocytes of patients with monoclonal gammopathies. <i>Clinical and Experimental Immunology</i> , 2008, 79, 100-104.	1.1	23
74	The idiotypic specificities of lymphocytes in human monoclonal gammopathies: analysis with the fluorescence activated cell sorter. <i>Clinical and Experimental Immunology</i> , 1983, 51, 173-7.	1.1	23
75	Intermediate-Dose Melphalan (100 mg/m ²)/Bortezomib/Thalidomide/Dexamethasone and Stem Cell Support in Patients with Refractory or Relapsed Myeloma. <i>Clinical Lymphoma and Myeloma</i> , 2006, 6, 475-477.	1.4	22
76	A phase II multi-center trial of pentostatin plus cyclophosphamide with ofatumumab in older previously untreated chronic lymphocytic leukemia patients. <i>Haematologica</i> , 2015, 100, e501-e504.	1.7	22
77	V β 39V α 2 T Cells in the Bone Marrow of Myeloma Patients: A Paradigm of Microenvironment-Induced Immune Suppression. <i>Frontiers in Immunology</i> , 2018, 9, 1492.	2.2	21
78	Differential expression of ecto-5' nucleotidase activity by functionally and phenotypically distinct subpopulations of human Leu-2+/T8+ lymphocytes. <i>Journal of Immunology</i> , 1986, 137, 484-9.	0.4	21
79	Inhibition of the mevalonate pathway to override chemoresistance and promote the immunogenic demise of cancer cells. <i>Oncolmmunology</i> , 2013, 2, e25770.	2.1	20
80	Idiotype-specific immunotherapy in multiple myeloma: suggestions for future directions of research. <i>Haematologica</i> , 2006, 91, 941-8.	1.7	19
81	Multiple Myeloma: Beta-2-Microglobulin is not a Useful Follow-Up Parameter. <i>Acta Haematologica</i> , 1989, 82, 122-125.	0.7	18
82	Lack of Correlation between Plasma Cell Thymidine Labelling Index and Serum Beta-2-Microglobulin in Monoclonal Gammopathies. <i>Acta Haematologica</i> , 1987, 78, 239-242.	0.7	17
83	A Phase II Study of Chlorambucil Plus Rituximab Followed by Maintenance Versus Observation In Elderly Patients with Previously Untreated Chronic Lymphocytic Leukemia: Results of the First Interim Analysis. <i>Blood</i> , 2010, 116, 2462-2462.	0.6	17
84	Increased expression of non-functional killer inhibitory receptor CD94 in CD8+ cells of myeloma patients. <i>British Journal of Haematology</i> , 2000, 109, 46-53.	1.2	16
85	ABCA1, apoA-I, and BTN3A1: A Legitimate M ϕ Age Δ Trois in Dendritic Cells. <i>Frontiers in Immunology</i> , 2018, 9, 1246.	2.2	16
86	Molecular dynamics of targeting CD38 in multiple myeloma. <i>British Journal of Haematology</i> , 2021, 193, 581-591.	1.2	16
87	Comparison of purine degradative enzymes and terminal deoxynucleotidyl transferase in T cell leukaemias and in normal thymic and post-thymic T cells. <i>British Journal of Haematology</i> , 1983, 54, 451-457.	1.2	16
88	V β 39V α 2 T Cells as Strategic Weapons to Improve the Potency of Immune Checkpoint Blockade and Immune Interventions in Human Myeloma. <i>Frontiers in Oncology</i> , 2018, 8, 508.	1.3	15
89	The generation of alloreactive cytotoxic T lymphocytes requires the expression of ecto-5' nucleotidase activity. <i>Journal of Immunology</i> , 1988, 141, 3768-75.	0.4	15
90	Mitochondrial metabolism: Inducer or therapeutic target in tumor immune-resistance?. <i>Seminars in Cell and Developmental Biology</i> , 2020, 98, 80-89.	2.3	14

#	ARTICLE	IF	CITATIONS
91	Multiple myeloma: ecto-5' nucleotidase deficiency of suppressor/cytotoxic (CD8) lymphocytes is a marker for the expansion of suppressor T cells. <i>Clinical and Experimental Immunology</i> , 1987, 69, 426-32.	1.1	14
92	Altered expression of growth-regulated protooncogenes in human malignant plasma cells. <i>Cancer Research</i> , 1989, 49, 4701-4.	0.4	14
93	Immunomodulatory and clinical effects of daratumumab in Tâ€cell acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2020, 191, e28-e32.	1.2	13
94	Humoral immune responses toward tumor-derived antigens in previously untreated patients with chronic lymphocytic leukemia. <i>Oncotarget</i> , 2017, 8, 3274-3288.	0.8	13
95	Multiple myeloma: biological and clinical significance of bone marrow plasma cell labelling index. <i>Haematologica</i> , 1987, 72, 171-5.	1.7	13
96	Idiotypic vaccination in B-cell malignancies. <i>Trends in Molecular Medicine</i> , 1997, 3, 435-441.	2.6	12
97	Differential Effects of Microenvironmental Elements On Tumor Cells Survival in Chronic Lymphocytic Leukemia Patient Subsets with Good or Poor Prognosis.. <i>Blood</i> , 2009, 114, 2333-2333.	0.6	12
98	The human myeloma cell line LP-1: a versatile model in which to study early plasma-cell differentiation and c-myc activation. <i>Blood</i> , 1989, 73, 1020-7.	0.6	12
99	Decreased ecto-5'nucleotidase activity of peripheral blood lymphocytes in human monoclonal gammopathies: correlation with tumor cell kinetics. <i>Blood</i> , 1985, 65, 530-534.	0.6	11
100	A Score-Based Approach to 18F-FDG PET Images as a Tool to Describe Metabolic Predictors of Myocardial Doxorubicin Susceptibility. <i>Diagnostics</i> , 2017, 7, 57.	1.3	11
101	Tailoring CD19xCD3-DART exposure enhances T-cells to eradication of B-cell neoplasms. <i>Oncolmmunology</i> , 2018, 7, e1341032.	2.1	11
102	Transfer of the interleukin-2 gene into human cancer cells induces specific antitumor recognition and restores the expression of CD3/T-cell receptor associated signal transduction molecules. <i>Blood</i> , 1997, 89, 212-8.	0.6	11
103	Comprehensive assessment of the TCRBV repertoire in small T-cell samples by means of an improved and convenient multiplex PCR method. <i>Experimental Hematology</i> , 2009, 37, 728-738.	0.2	10
104	CD3-induced T-cell activation in the bone marrow of myeloma patients: major role of CD4+cells. <i>British Journal of Haematology</i> , 1995, 90, 625-632.	1.2	9
105	Chlorambucil plus rituximab as front-line therapy for elderly and/or unfit chronic lymphocytic leukemia patients: correlation with biologically-based risk stratification. <i>Haematologica</i> , 2017, 102, e352-e355.	1.7	9
106	CD157 signaling promotes survival of acute myeloid leukemia cells and modulates sensitivity to cytarabine through regulation of anti-apoptotic Mcl-1. <i>Scientific Reports</i> , 2021, 11, 21230.	1.6	8
107	Multiple myeloma: altered CD4/CD8 ratio in bone marrow. <i>Haematologica</i> , 1990, 75, 129-31.	1.7	8
108	Activated idiotype-reactive cells in suppressor/cytotoxic subpopulations of monoclonal gammopathies: correlation with diagnosis and disease status. <i>Blood</i> , 1988, 72, 1064-8.	0.6	8

#	ARTICLE	IF	CITATIONS
109	Clinical and Immunological Studies in Advanced Cancer Patients Sequentially Treated with Anti CD3 Monoclonal Antibody (OKT3) and Interleukin-2. <i>Leukemia and Lymphoma</i> , 1996, 21, 325-330.	0.6	7
110	Risk factors for dementia of Alzheimer's type: A case-control, retrospective evaluation. <i>Archives of Gerontology and Geriatrics</i> , 2001, 33, 253-259.	1.4	7
111	Stem cell transplantation in multiple myeloma and other plasma cell disorders (report from an EBMT Tj ETQq1 1 0.784314 rgBT /Ove	0.6	7
112	Idiotypic vaccination as therapy for multiple myeloma. <i>Seminars in Hematology</i> , 1999, 36, 34-7.	1.8	7
113	T Cells in Multiple Myeloma: Is This a Reliable Population to Count on as Antitumor Effector Cells?. <i>Leukemia and Lymphoma</i> , 1995, 17, 63-70.	0.6	6
114	Immunoglobulin M (IgM) multiple myeloma versus Waldenström macroglobulinemia: diagnostic challenges and therapeutic options: two case reports. <i>Journal of Medical Case Reports</i> , 2020, 14, 75.	0.4	6
115	Amplification of T Cell Activation Induced by CD73 (Ecto-5' Nucleotidase) Engagement. <i>Advances in Experimental Medicine and Biology</i> , 1991, 309B, 155-158.	0.8	6
116	Rituximab Plus Chlorambucil As Initial Treatment for Elderly Patients with Chronic Lymphocytic Leukemia (CLL): Effect of Pre-Treatment Biological Characteristics and Gene Expression Patterns on Response to Treatment. <i>Blood</i> , 2011, 118, 294-294.	0.6	6
117	Generation of anti-tumour activity by OKT3-stimulation in multiple myeloma: in vitro inhibition of autologous haemopoiesis. <i>British Journal of Haematology</i> , 1994, 87, 494-502.	1.2	5
118	Comparison of purine degradative enzymes and terminal deoxynucleotidyl transferase in T cell leukaemias and in normal thymic and post-thymic T cells. <i>British Journal of Haematology</i> , 1983, 54, 451-457.	1.2	5
119	Biochemical and immunologic abnormalities in peripheral blood T lymphocytes of patients with hemophilia A. <i>European Journal of Haematology</i> , 1988, 41, 334-340.	1.1	5
120	Immune Reconstitution and Thymic Function After Reduced Intensity Allogeneic Hematopoietic Cell Transplantation. <i>Blood</i> , 2010, 116, 1254-1254.	0.6	5
121	Patterns of neutralizing humoral response to SARS-CoV-2 infection among hematologic malignancy patients reveal a robust immune response in anti-cancer therapy-naïve patients. <i>Blood Cancer Journal</i> , 2022, 12, 8.	2.8	5
122	Emergence of activated lymphocytes in CD4 and CD8 subpopulations of multiple myeloma: correlation with the expansion of suppressor T-cells (CD8+ OKM1+) and ecto-5' nucleotidase deficiency. <i>Journal of Clinical & Laboratory Immunology</i> , 1988, 26, 89-95.	0.1	5
123	Monoclonal Immunoglobulin Gene Rearrangement in Peripheral Lymphocytes of a Patient with Multiple Myeloma. <i>Tumori</i> , 1989, 75, 1-3.	0.6	4
124	B cells from chronic lymphocytic leukemia (CLL) patients are strong inducers of proliferation and major histocompatibility complex (MHC)-unrestricted [natural killer (NK)-like] cytotoxicity in normal T-lymphocytes. <i>Journal of Clinical Immunology</i> , 1989, 9, 329-337.	2.0	4
125	Bendamustine and subcutaneous alemtuzumab combination is an effective treatment in relapsed/refractory chronic lymphocytic leukemia patients. <i>Haematologica</i> , 2014, 99, e159-e161.	1.7	4
126	Metabolic approaches to rescue antitumor V gamma 9V delta 2 T-cell functions in myeloma. <i>Frontiers in Bioscience - Landmark</i> , 2020, 25, 69-105.	3.0	4

#	ARTICLE	IF	CITATIONS
127	Phenotypic and functional analysis of peripheral blood lymphocytes during interferon-alpha 2b therapy in multiple myeloma patients with low tumor mass. <i>Haematologica</i> , 1991, 76, 383-8.	1.7	4
128	CD38 stimulation lowers the activation threshold and enhances the alloreactivity of cord blood T cells by activating the phosphatidylinositol 3-kinase pathway and inducing CD73 expression. <i>Journal of Immunology</i> , 1999, 162, 6238-46.	0.4	4
129	Clinicopathologic spectrum of cutaneous diseases in patients with hematologic malignancies with or without allogeneic bone marrow transplantation: an observational cohort study in 101 patients. <i>Giornale Italiano Di Dermatologia E Venereologia</i> , 2013, 148, 453-63.	0.8	4
130	Difference in Polyamine Transport in Human B and T Lymphocytes. <i>Biological Chemistry Hoppe-Seyler</i> , 1991, 372, 75-78.	1.4	3
131	Idiotype Vaccination of Myeloma Patients After Chemotherapy. <i>Acta Oncologica</i> , 2000, 39, 807-808.	0.8	3
132	Sequential administration of OKT3 (anti-CD3) and interleukin-2 in two patients with chemoresistant hematological disease. <i>European Journal of Haematology</i> , 1992, 49, 150-152.	1.1	3
133	Aminobisphosphonates, statins and the mevalonate pathway: a cross-road to fine-tune the activation of NK and V β 9V β 2 T cells. <i>IBMS BoneKey</i> , 2012, 9, .	0.1	3
134	Atypical Chronic Myeloid Leukemia: New Developments from Molecular Diagnosis to Treatment. <i>Medicina (Lithuania)</i> , 2021, 57, 1104.	0.8	3
135	The Use of Ibrutinib in Italian CLL Patients Treated in a Real-World Setting (EVIDENCE): A Preliminary Report. <i>Blood</i> , 2021, 138, 4684-4684.	0.6	3
136	Decreased ecto-5' nucleotidase activity of peripheral blood lymphocytes in human monoclonal gammopathies: correlation with tumor cell kinetics. <i>Blood</i> , 1985, 65, 530-4.	0.6	3
137	A Position Paper on IgM-Enriched Intravenous Immunoglobulin Adjunctive Therapy in Severe Acute Bacterial Infections: The TO-PIRO SCORE Proposal. <i>New Microbiologica</i> , 2019, 42, 176-180.	0.1	3
138	How COVID-19 pandemic changed our attitude to venetoclax-based treatment in chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2022, , 1-4.	0.6	3
139	Cytobiological Studies in Multiple Myeloma. <i>Acta Haematologica</i> , 1987, 78, 41-42.	0.7	2
140	Behavioral disturbances in the Alzheimer's care units: A six-months observation. <i>Archives of Gerontology and Geriatrics</i> , 2001, 33, 245-252.	1.4	2
141	Immunologic and virologic findings in hemophiliacs do not correlate with ecto-5' nucleotidase activity of peripheral blood lymphocytes. A difference with homosexual men. <i>European Journal of Haematology</i> , 1987, 38, 310-314.	1.1	2
142	Advances in biology of multiple myeloma: Cell kinetics, molecular biology and immunology. <i>European Journal of Haematology</i> , 1989, 43, 30-34.	1.1	2
143	Dipyridamole <i>in vitro</i> suppresses the generation of T cell cytotoxic functions: Synergistic activity with cyclosporine. <i>European Journal of Haematology</i> , 1991, 46, 6-10.	1.1	2
144	Efficacy and Safety of a First-Line Combined Therapeutic Approach for Young CLL Patients Stratified According to the Biological Prognostic Features: First Analysis of the GIMEMA Multicenter LLC0405 Study. <i>Blood</i> , 2008, 112, 3167-3167.	0.6	2

#	ARTICLE	IF	CITATIONS
145	Unmutated IGHV1-69/D3-16/J3 Stereotyped HCDR3 Rearrangements (Subset 6) Are Associated with Indolent Disease Course and Have Outcome Independent of Mutational Status In Early Stage CLL (Rai 0). Blood, 2010, 116, 1371-1371.	0.6	2
146	Efficacy and Safety of a First Line Combined Therapeutic Approach for Young CLL Patients with Advanced or Progressive Disease Stratified According to the Biologic Features: First Analysis of the GIMEMA Multicenter Study LLC0405. Blood, 2010, 116, 2471-2471.	0.6	2
147	A Phase II Multi-Center Trial Of Pentostatin Plus Cyclophosphamide With Ofatumumab (PCO) In Older Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients. Blood, 2013, 122, 4177-4177.	0.6	2
148	A phase II study of chlorambucil plus rituximab followed by maintenance versus observation in elderly patients with previously untreated chronic lymphocytic leukemia: Results of the induction phase.. Journal of Clinical Oncology, 2011, 29, 6629-6629.	0.8	2
149	Idiotype Vaccination in Human Myeloma: Generation of Tumor-Specific Immune Responses After High-Dose Chemotherapy. Blood, 1999, 94, 673-683.	0.6	2
150	Progressive telomere shortening is part of the natural history of chronic lymphocytic leukaemia and impacts clinical outcome: evidences from long term follow-up. British Journal of Haematology, 2018, 181, 693-695.	1.2	1
151	Diagnosis of maternal Hodgkin lymphoma following abnormal findings at noninvasive prenatal screening test (NIPT): Report of two cases. Clinical Case Reports (discontinued), 2021, 9, 1066-1071.	0.2	1
152	Abstract 2122: Induction of structural and functional effects of myeloma cells after daratumumab treatment. , 2018, , .		1
153	Immune Checkpoint Blockade Combinations As Promising Strategy for Cancer Immunotherapy in Multiple Myeloma Patients. Blood, 2016, 128, 2059-2059.	0.6	1
154	A Comparative Study of Biosimilar Filgrastim Versus Originator G-CSF for CD34+ Cells Mobilization and Autografting in Hematological Malignancies. Blood, 2016, 128, 2183-2183.	0.6	1
155	Efficacy and Safety of Front-Line Venetoclax and Rituximab (VenR) for the Treatment of Young Patients with Chronic Lymphocytic Leukemia and an Unfavorable Biologic Profile. Preliminary Results of the Gimema Study 'Veritas'. Blood, 2020, 136, 47-49.	0.6	1
156	Biochemical evidence for the presence of abnormal B lymphocytes in the peripheral blood of multiple myeloma patients. Alabama Journal of Medical Sciences, 1987, 24, 400-4.	0.1	1
157	Soluble factor(s) released by Concanavalin A activated lymph node lymphocytes induce proliferation and maturation of chronic lymphocytic leukaemia (CLL) B lymphocytes. Journal of Clinical & Laboratory Immunology, 1984, 13, 85-8.	0.1	1
158	Changes in SRBC binding capacity and T-surface antigen expression on human peripheral blood lymphocytes stimulated by 12-O-tetradecanoylphorbol-13-acetate (TPA). Journal of Clinical & Laboratory Immunology, 1983, 12, 57-61.	0.1	1
159	Usefulness of frequency analysis of cytotoxic T-lymphocytes precursors (CTL-p) for selection of HLA matched unrelated marrow donors. Panminerva Medica, 1995, 37, 168-70.	0.2	1
160	Cyclosporin A and dipyridamole: An effective combination against the generation of cytotoxic T lymphocytes (CTL). Pharmacological Research, 1992, 26, 12-13.	3.1	0
161	Reversible Bronchial Hyperresponsiveness Induced by OK-T3/IL-2 Administration in a Patient with Multiple Myeloma. Respiration, 1995, 62, 228-231.	1.2	0
162	2.28 Identification by Serological Proteome Analysis (SERPA) of Novel Tumor Associated Antigens in Chronic Lymphocytic Leukemia (CLL). Clinical Lymphoma, Myeloma and Leukemia, 2011, 11, S176-S177.	0.2	0

#	ARTICLE	IF	CITATIONS
163	2.37 Accelerated Activity of the Mevalonate Pathway Supports the Immune Escape and Multidrug-Resistance Phenotype of IGHV Unmutated Chronic Lymphocytic Leukemia Cells. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011, 11, S182.	0.2	0
164	5.9 Bendamustine and Alemtuzumab Combination in Relapsed and Refractory Chronic Lymphocytic Leukemia: Interim Report of the Italian Trial. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011, 11, S247-S248.	0.2	0
165	The CXCR4 Downstream Signaling Pathways in Chronic Lymphocytic Leukemia: a Target to Reverse Microenvironment Protection. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, S42.	0.2	0
166	A MRD-GUIDED APPROACH FOR THE COMBINATION OF IBRUTINIB TO VENETOCLAX IN RELAPSED/REFRACTORY PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (IMPROVE STUDY). <i>Hematological Oncology</i> , 2017, 35, 426-427.	0.8	0
167	Regulation of HIF-1 $\hat{\pm}$ in TP53 Disrupted Chronic Lymphocytic Leukemia Cells and Its Potential Role as a Therapeutic Target. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, S214.	0.2	0
168	Anticancer innovative therapy: Highlights from the ninth annual meeting. <i>Cytokine and Growth Factor Reviews</i> , 2020, 51, 1-9.	3.2	0
169	Acute Myeloid Leukemia-Derived Dendritic Cells Express the Immunoregulatory Enzyme Indoleamine 2,3-dioxygenase.. <i>Blood</i> , 2006, 108, 1899-1899.	0.6	0
170	Quantitative Molecular Expression of the Immunoregulatory Enzyme Indoleamine 2,3-Dioxygenase in Acute Myeloid Leukemia Cells as a Possible Marker for Minimal Residual Disease Detection.. <i>Blood</i> , 2007, 110, 4229-4229.	0.6	0
171	Telomere Length Is An Independent Predictor of Survival, Treatment Requirement and Richterâ€™s Syndrome Transformation in Chronic Lymphocytic Leukemia.. <i>Blood</i> , 2008, 112, 1052-1052.	0.6	0
172	Identification by Serological Proteome Analysis (SERPA) of Tumor-Associated Antigens Eliciting Antibody Responses In Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2010, 116, 917-917.	0.6	0
173	The Defective Proliferation of Vgamma9Vdelta2 T Cells to Zoledronic Acid In Chronic Lymphocytic Leukemia (CLL) Is a Powerful Time to First Treatment (TFT) Predictor Associated with the IGHV Mutational Status. <i>Blood</i> , 2010, 116, 3602-3602.	0.6	0
174	IGHV Unmutated Chronic Lymphocytic Leukemia (CLL) B Cells Are More Susceptible to Spontaneous Apoptosis Than Mutated CLL B Cells and Are Subject to the Anti-Apoptotic Effect of Environmental Signals. <i>Blood</i> , 2010, 116, 2431-2431.	0.6	0
175	Progressive Telomere Shortening Is Part of the Natural History of Chronic Lymphocytic Leukemia (CLL) and Impacts Clinical Outcome. <i>Blood</i> , 2011, 118, 2845-2845.	0.6	0
176	The Mevalonate Pathway As a Metabolic Target to Circumvent Multidrug-Resistance in Chronic Lymphocytic Leukemia Cells. <i>Blood</i> , 2011, 118, 735-735.	0.6	0
177	Final Report of Bendamustine and Alemtuzumab (BEN CAM) Combination in Relapsed and Refractory Chronic Lymphocytic Leukemia.. <i>Blood</i> , 2012, 120, 2898-2898.	0.6	0
178	The Mevalonate Pathway and Downstream Signal Transducers As Therapeutic Targets to Overcome Multidrug Resistance in Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2012, 120, 3881-3881.	0.6	0
179	Identification of Novel Tumor-Associated Antigens in Chronic Lymphocytic Leukemia (CLL) by Serological Proteome Analysis (SERPA). <i>Blood</i> , 2012, 120, 3878-3878.	0.6	0
180	The Mevalonate Metabolic Pathway and the CXCL12/CXCR4 Axis Reciprocally Interact and Are Implicated in Fludarabine Resistance of Chronic Lymphocytic Leukemia Cells. <i>Blood</i> , 2014, 124, 833-833.	0.6	0

#	ARTICLE	IF	CITATIONS
181	A Molecular Model to Predict Durable Remission after First Line Fludarabine-Cyclophosphamide-Rituximab Treatment in Chronic Lymphocytic Leukemia. Blood, 2014, 124, 3300-3300.	0.6	0
182	The Hypoxia-Inducible Factor-1alpha Is Constitutively Upregulated in TP53 Disrupted CLL Cells: A Potential Target to Overcome Fludarabine Resistance. Blood, 2015, 126, 2925-2925.	0.6	0
183	Chlorambucil PLUS Rituximab As FRONT-LINE Therapy for Elderly and/or Unfit CLL Patients. LONG-TERM Follow-up and Correlation with Biologic-Based Risk Stratification. Blood, 2016, 128, 3240-3240.	0.6	0
184	Prolonged Follow-up Confirmed a Role for Upfront Tandem Auto-Allo Transplant in Multiple Myeloma Also in the Era of New Drugs. Blood, 2016, 128, 3469-3469.	0.6	0
185	ATP-Binding-Cassette A1 Regulates Extracellular Isopentenyl Pyrophosphate Release and $\hat{V}^{\hat{3}}\hat{V}^{\hat{2}}$ T-Cell Activation By Dendritic Cells. Blood, 2016, 128, 3709-3709.	0.6	0
186	HIF-1 $\hat{\pm}$ Upregulation in TP53 Disrupted Chronic Lymphocytic Leukemia Cells and Its Potential Role As a Therapeutic Target. Blood, 2016, 128, 305-305.	0.6	0
187	Cost efficiency and effectiveness of biosimilar filgrastim in autologous transplant. Bone Marrow Transplantation, 2021, , .	1.3	0
188	Monoclonal immunoglobulin gene rearrangement in peripheral lymphocytes of a patient with multiple myeloma. Tumori, 1989, 75, 1-3.	0.6	0
189	Immune dysregulation in monoclonal gammopathies. Bone Marrow Transplantation, 1989, 4 Suppl 1, 165-7.	1.3	0